Otsuka is pioneering next-generation therapeutics and drug delivery systems to address the world's most challenging diseases. Headquartered in Tokyo, operating globally.
Founded with a vision to create new products for better health worldwide, Otsuka develops breakthrough pharmaceutical compounds and advanced biologic therapies. Our research spans oncology, neuroscience, cardiovascular medicine, and rare diseases.
Our integrated technology stack spans the full drug development lifecycle — from computational target discovery to clinical-grade manufacturing and real-world evidence generation.
AI-powered compound screening and molecular optimization platform capable of evaluating millions of candidates per cycle. Reduces early-stage discovery timelines by up to 60%.
Proprietary AAV vector engineering and CRISPR-based editing tools designed for high-efficiency gene delivery with minimal off-target effects across multiple tissue types.
Biodegradable polymer-based depot injections and oral controlled-release systems providing weeks-long therapeutic coverage from a single administration.
Sensor-enabled medication tracking and companion digital health applications that improve patient adherence and generate real-world outcomes data at scale.
Proprietary multi-omics biomarker identification suite for patient stratification, enabling precision enrollment in clinical trials and personalized treatment regimens.
End-to-end biologics manufacturing capability with continuous processing technology, delivering clinical and commercial-scale production under full regulatory compliance.
Our leadership brings decades of experience from the world's leading pharmaceutical companies, research institutions, and regulatory agencies.
Chief Executive Officer
Chief Scientific Officer
Chief Operating Officer
VP, Drug Discovery
VP, Clinical Development
Head of Genomic Medicine
Chief Financial Officer
Head of Regulatory Affairs
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to OTS-4187, Otsuka's investigational treatment for advanced hepatocellular carcinoma, based on promising Phase II results.
Recognized for pioneering contributions to sustained-release drug delivery and digital therapeutics integration, Otsuka was awarded the prestigious Global Pharma Innovation Award in Geneva.
Otsuka announced positive topline results from its pivotal RESTORE-1 trial, demonstrating statistically significant improvement in enzyme activity levels in patients with lysosomal storage disease.
Otsuka enters a multi-year collaboration with Kyoto University's Institute for Integrated Cell-Material Sciences to accelerate identification of novel indications for existing approved compounds.
The state-of-the-art 50,000 sqm facility features continuous bioprocessing capabilities and will support commercial-scale production of monoclonal antibodies and cell therapies beginning in 2026.
We are assembling a world-class team of scientists, engineers, and healthcare professionals. Otsuka offers competitive compensation, cutting-edge laboratory facilities, and the opportunity to impact millions of patients worldwide.
Design and synthesize novel small molecule therapeutics. PhD in organic/medicinal chemistry required. 5+ years pharmaceutical industry experience preferred. Tokyo, Japan.
Lead AAV vector development and optimization programs. Experience with in vivo gene delivery and CRISPR technologies essential. Osaka, Japan.
Design and analyze Phase I-III clinical studies across therapeutic areas. MS/PhD in biostatistics or related field. Remote-friendly with quarterly travel to Tokyo.
For partnership inquiries, investor relations, or general questions, reach out to our team.
contact@otsuka.tel